Tiziana Life Sciences Ltd.’s stock TLSA soared 54% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new drug application for intranasal foralumab, a treatment for Alzheimer’s disease. “Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain,” the company said in a statement. The move will allow the company to move the anti-CD3 monoclonal antibody…
